Company / Return on Assets (ROA)
Candel Therapeutics, Inc. Return on Assets (ROA) History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-92.1%
FY2023
5-year range
-92.1% / -19.8%
FY2021-FY2023
Trend
-98.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -19.8% to -92.1% over the past 2 years.
Based on SEC 10-K filings.
-92.1% in FY2023.
Declined from -19.8% to -92.1% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, return on assets (roa) decreased 98.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | -92.1% | -98.0% |
| FY2022 | -46.5% | -134.6% |
| FY2021 | -19.8% | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026